Nitazoxanide
- Generic Name
- Nitazoxanide
- Brand Names
- Alinia, Busulfex
- Drug Type
- Small Molecule
- Chemical Formula
- C12H9N3O5S
- CAS Number
- 55981-09-4
- Unique Ingredient Identifier
- SOA12P041N
- Background
Nitazoxanide belongs to the class of drugs known as thiazolides. Nitazoxanide (NTZ) is a broad-spectrum anti-infective drug that markedly modulates the survival, growth, and proliferation of a range of extracellular and intracellular protozoa, helminths, anaerobic and microaerophilic bacteria, in addition to viruses. This drug is effective in the treatment of gastrointestinal infections including Cryptosporidium parvum or Giardia lamblia in healthy subjects. It is generally well tolerated. Nitazoxanide is a first-line, standard treatment for illness caused by C. parvum or G. lamblia infection in healthy (not immunosuppressed) adults and children and may also be considered in the treatment of illnesses caused by other protozoa or helminths . Recently, this drug has been studied as a broad-spectrum antiviral agent due to its ability to inhibit the replication of several RNA and DNA viruses .
- Indication
用于治疗隐孢子虫、贾第鞭毛虫、阿米巴原虫引起的原虫性腹泻。
- Associated Conditions
- Diarrhea caused by Cryptosporidium parvum, Diarrhea caused by Giardia lamblia
- Associated Therapies
- -
Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Colds Due to Enterovirus/Rhinovirus Infection
- Conditions
- EnterovirusRhinovirus
- Interventions
- First Posted Date
- 2020-07-28
- Last Posted Date
- 2024-10-17
- Lead Sponsor
- Romark Laboratories L.C.
- Target Recruit Count
- 214
- Registration Number
- NCT04489381
- Locations
- 🇺🇸
HealthStar Research LLC, Hot Springs, Arkansas, United States
🇺🇸Invesclinic US LLC, Fort Lauderdale, Florida, United States
🇺🇸RH Medical Urgent Care, Bronx, New York, United States
Trial to Evaluate Efficacy and Safety of Nitazoxanide in the Treatment of Mild or Moderate COVID-19
- Conditions
- COVID-19
- Interventions
- First Posted Date
- 2020-07-24
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Romark Laboratories L.C.
- Target Recruit Count
- 935
- Registration Number
- NCT04486313
- Locations
- 🇺🇸
Invesclinic US LLC, Fort Lauderdale, Florida, United States
🇺🇸RH Medical Urgent Care, Bronx, New York, United States
Efficacy and Safety Study of Nitazoxanide (NTX) in the Treatment of Patients With SARS-CoV-2 Virus Infection (COVID-19)
- First Posted Date
- 2020-07-09
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Laboratorios Roemmers S.A.I.C.F.
- Target Recruit Count
- 135
- Registration Number
- NCT04463264
- Locations
- 🇦🇷
Hospital Universitario Austral, Presidente Derqui, Buenos Aires, Argentina, Argentina
Efficacy and Safety of Nitazoxanide 600 mg to Treat Mild Ambulatory COVID-19 Patients
- First Posted Date
- 2020-06-22
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- Azidus Brasil
- Registration Number
- NCT04441398
Efficacy and Safety of Nitazoxanide for Post Exposure Prophylaxis of COVID-19
- First Posted Date
- 2020-06-17
- Last Posted Date
- 2022-10-28
- Lead Sponsor
- Azidus Brasil
- Registration Number
- NCT04435314
Efficacy and Safety of Nitazoxanide 600 mg BID Versus Placebo for the Treatment of Hospitalized Patients With COVID-19
- First Posted Date
- 2020-06-09
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- Azidus Brasil
- Target Recruit Count
- 380
- Registration Number
- NCT04423861
- Locations
- 🇧🇷
Hospital Vera Cruz, Campinas, São Paulo, Brazil
Study of Nitazoxanide (NTZ) for Helicobacter Pylori in Children
- Conditions
- Helicobacter Pylori Infection
- Interventions
- First Posted Date
- 2020-06-04
- Last Posted Date
- 2020-06-04
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 100
- Registration Number
- NCT04415983
- Locations
- 🇪🇬
Sherief Abd-Elsalam, Tanta, Egypt
Novel Regimens in COVID-19 Treatment
- First Posted Date
- 2020-05-11
- Last Posted Date
- 2020-12-04
- Lead Sponsor
- Tanta University
- Target Recruit Count
- 160
- Registration Number
- NCT04382846
- Locations
- 🇪🇬
Tanta University, Assiut University, Tanta, Egypt
🇪🇬Sherief Abd-Elsalam, Tanta, Egypt
Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Pre- and Post Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses (VRI) in Healthcare Workers and Others at Increased Risk of SARS-CoV-2 Infection
- Conditions
- COVID-19Viral Respiratory Illnesses
- Interventions
- First Posted Date
- 2020-04-24
- Last Posted Date
- 2024-06-26
- Lead Sponsor
- Romark Laboratories L.C.
- Target Recruit Count
- 1407
- Registration Number
- NCT04359680
- Locations
- 🇺🇸
The Chappel Group Research, Kissimmee, Florida, United States
🇺🇸Chicago Medical Research Institute, Inc., Chicago, Illinois, United States
🇺🇸Chicago Clinical Research Institute, Inc., Chicago, Illinois, United States
Trial to Evaluate the Efficacy and Safety of Nitazoxanide (NTZ) for Post-Exposure Prophylaxis of COVID-19 and Other Viral Respiratory Illnesses in Elderly Residents of Long-Term Care Facilities (LTCF)
- Conditions
- COVID-19Viral Respiratory Illnesses
- Interventions
- First Posted Date
- 2020-04-13
- Last Posted Date
- 2024-07-08
- Lead Sponsor
- Romark Laboratories L.C.
- Target Recruit Count
- 190
- Registration Number
- NCT04343248
- Locations
- 🇺🇸
The Chappel Group Research, Kissimmee, Florida, United States
🇺🇸Clinical Trial Specialists, Inc., Acworth, Georgia, United States
🇺🇸Centex Studies, Inc., Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.